By now, you’ve likely seen dosist on social media or on the Internet somewhere. The compact, disposable, dose-controlled cannabis pen is incredibly popular in the United States and more recently have been promoting themselves in the Canadian market. There is just one issue: although cannabis will become legal as of July 1, a product like dosist–that offers dose-controlled pens that provides safe access to the positive benefits of cannabis through their six proprietary formulas: bliss, sleep, calm, relief, arouse, passion—will not be legal at least for another year, or at all.
The challenge is something that doesn’t phase SoYoung Park, the Head of Product Development for dosist. As someone who previously worked in Palo Alto on brands like Universal Pictures and Disney Pictures & Television, she is used to facing challenges and marching to the beat of her own drum. We had the opportunity to sit down with her and ask, why dosist and why now? Read the interview below:
Edit Seven: Working in tech in Palo Alto must be totally different that working in the world of cannabis. How did you make the transition?
SoYoung Park: I’ve always wanted to be part of creating evocative, effective experiences, whether that takes the form of a five star movie, five star hotel, prosthetic foot, or robotic arm. My role at dosist integrates everything I’ve learned about product design, storytelling, strategy, and execution from some of the best across a number of seemingly disparate businesses, all with the goal of delivering transformational products for our consumers. Don’t get me wrong, I’m challenged every single day, but working at dosist isn’t as different as you might think from working at other great organizations pushing against their creative edges.
E7: Since the 60s, there has always been a negative connotation associated with ‘stoners’. Is the culture changing?
SP: Without a doubt, cannabis is becoming broadly accepted. Nationally, nearly 70% of adults approve of cannabis as a therapeutic tool. With that, “cannabis subculture”–at one time dominated by a single narrative around getting high–is shifting to a diverse, popularized, nuanced marketplace. Consumers are learning how cannabis can address a wide array of needs. And the number of product options now available (ours being the best of course) empowers them to experiment and discover the personalized benefits for themselves.
E7: What has your own cannabis journey looked like?
SP: Cannabis was typically an ingredient in which I’d occasionally indulge for pleasure or play. Now, I use our pens more for purposeful recovery or targeted relief. I know I’m not alone when I say I’m a terrible sleeper or that too often, stress or overwhelm derails an otherwise well-intentioned day. Our pens de-fang those moments and moods and help me get back to a better (well-rested) version of myself.
E7: The dosist brand is stunning, so one has to ask: How intrinsic is design to the dosist brand and does it affect the overall product?
SP: Human-centered design is an inextricable part of the dosist DNA. We’re obsessed with providing people with access to safe and precisely dosed wellness solutions. But no solution will truly become a part of a modern, savvy consumer’s everyday life unless that solution is delivered via a product and experience that is intelligent, intuitive, credible, and beautiful. These attributes lie at the very heart of good design, and we work doggedly to deliver on that promise.
E7: The cannabis industry seems to have more and more powerful women at the helm leading multi-million-dollar businesses and it doesn’t seem to stop! How do you feel about that?
SP: Multi-billion. But frankly it’s not the market size that’s as inspiring to me as the people in the space itself. The sheer eclecticism, technical depth, and ambition of the women AND men currently working in cannabis (plus the exceptional talent diving in) keeps me on my toes. From software developers, engineers, and designers to scientists, doctors, policy makers, and people from the service industry, agri-tech, mass production–this business is flooded with some of the most creative thinkers and doers across an insane breadth of disciplines working shoulder to shoulder. It’s a blast learning from and collaborating with them.
E7: What are you most excited about with legalization happening in Canada and what can people expect from dosist in 2018?
SP: We have products in the pipeline all in different stages of development, to be launched in the coming months and year ahead. As the first G20 country to make cannabis widely available, Canada will not only shift global attitudes around cannabis, but also spark broader policy change around how we can make this therapeutic ingredient more accessible.
I’m especially excited to collaborate with the community of scientists and clinicians in Canada. In truth, the endocannabinoid system, which plays a role in modulating our mood, our appetites and our core states of being, was only discovered in 1992. We are *just* at the beginning of understanding how this critical system works, much less how cannabis (a complex plant in and of itself) interacts with it. The opportunity to partner with experts across the human performance spectrum (physical, cognitive, emotional) is my favourite job perk. I can’t wait to translate their expertise into a pipeline of even more impactful products.
For more information on dosist, please click HERE.
(Story by Contributing Editor, Ama Scriver)